Kura Oncology, Inc. (KUR)
FSX
Closed
Oct 23, 2026
Day's Range
8.6452 wk Range
6.15Overview - KUR - Kura Oncology, Inc.
Key Statistics
Valuation
Enterprise Value
239.89M
P/E (Trailing)
-2.71
P/E (Forward)
-3.70
PEG Ratio
-1.01
Price / Sales (TTM)
9.95
Price / Book
17.84
EV / EBITDA
-0.84
Profitability
Gross Margin
98.83%
Profit Margin
99.91%
Operating Margin
-349.76%
Return on Assets
-31.30%
Return on Equity
-167.70%
Ownership
Shares Outstanding
88.95M
Float
70.52M
Held by Insiders
1.39%
Held by Institutions
100.23%
Price stats
Beta
0.46
50-Day Avg
9.84
200-Day Avg
8.38
Market Cap - KUR - Kura Oncology, Inc.
Peers - KUR - Kura Oncology, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on FSX.
- KURFSXKura Oncology, Inc.768.61MMarket Cap+4.17%52-week change-2.72P/E (Trailing)99.91%Profit Margin
- ANLFSXAnalog Devices, Inc.166.10BMarket Cap+40.40%52-week change47.41P/E (Trailing)29.78%Profit Margin
- 0QFFSXModerna Inc.75.83BMarket Cap+88.13%52-week change25.27P/E (Trailing)-141.42%Profit Margin
- 1AEFSXargenx SE46.38BMarket Cap+7.13%52-week change36.55P/E (Trailing)32.26%Profit Margin
- 64BFSXAstera Labs, Inc.45.97BMarket Cap+48.68%52-week change176.19P/E (Trailing)30.74%Profit Margin
- 1AEAFSXargenx SE American Depositary Receipt45.90BMarket Cap-5.00%52-week change32.46P/E (Trailing)32.26%Profit Margin
- 42ZFSXRevolution Medicines, Inc.35.79BMarket Cap+70.06%52-week change-28.07P/E (Trailing)0.00%Profit Margin
Profile Summary - KUR - Kura Oncology, Inc.
About
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer. Kura Oncology’s current portfolio centers on precision oncology programs designed to target specific molecular drivers of disease, with an emphasis on hematologic malignancies and selected…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
